Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant chinese non-small cell lung cancer

Pathology and Oncology Research

Volumn 15, Issue 4, 2009, Pages 651-658

  Chen, Hua Jun ^a,b   Mok, Tony S ^c   Chen, Zhi Hong ^b   Guo, Ai Lin ^b   Zhang, Xu Chao ^b   Su, Jian ^b   Wu, Yi Long ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

C MET; Epidermal growth factor receptor; Non small cell lung cancer, Resistance; T790M

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CHINA; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 75049083402     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9167-8     Document Type: Article

References (27)

1. W Pao VA Miller KA Politi, et al. 2005 Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain PLoS Med 2 e73 10.1371/journal.pmed.0020073 15737014 (Pubitemid 40629469)
2. W Pao MN Balak GJ Riely, et al. 2006 Molecular analysis of NSCLC patients with acquired resistance to gefitinib or erlotinib J Clin Oncol 24 Suppl 383s abstract 7078
3. EL Kwak R Sordella DW Bell, et al. 2005 Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib Proc Natl Acad Sci USA 102 7665 7670 10.1073/pnas.0502860102 1:CAS:528:DC%2BD2MXkslOmsr0%3D 15897464 (Pubitemid 40741028)
4. S Kobayashi TJ Boggon T Dayaram, et al. 2005 EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 786 792 10.1056/NEJMoa044238 1:CAS:528:DC%2BD2MXhsFCiurk%3D 15728811 (Pubitemid 40271173)
5. CH Yun KE Mengwasser AV Toms, et al. 2008 The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci USA 105 2070 2075 10.1073/pnas.0709662105 1:CAS:528:DC%2BD1cXitl2mu7k%3D 18227510
6. JA Engelman K Zejnullahu T Mitsudomi, et al. 2007 MET amplification leads to gefitinib resistance in lung cancer by activating ErbB3 signaling Science 316 1039 1043 10.1126/science.1141478 1:CAS:528:DC%2BD2sXltlOjt7g%3D 17463250 (Pubitemid 46799492)
7. A Ogino H Kitao S Hirano, et al. 2007 Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line Cancer Res 67 7807 7814 10.1158/0008-5472.CAN- 07-0681 1:CAS:528:DC%2BD2sXptVGltrs%3D 17699786 (Pubitemid 47281375)
8. JA Engelman K Zejnullahu T Mitsudomi, et al. 2006 Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer J Clin Invest 116 2695 2706 10.1172/JCI28656 1:CAS:528:DC%2BD28XhtVKgu7vN 16906227 (Pubitemid 44511633)
9. YL Wu WZ Zhong LY Li, et al. 2007 Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China J Thorac Oncol 2 5 430 439 10.1097/01.JTO.0000268677.87496.4c 17473659 (Pubitemid 47181698)
10. MB Beasley E Brambilla WD Travis 2005 The 2004 World Health Organization classification of lung tumors Semin Roentgenol 40 90 97 10.1053/j.ro.2005.01.001 15898407 (Pubitemid 40417889)
11. G Ling A Persson B Berne, et al. 2001 Persistent p53 mutations in single cells from normal human skin Am J Pathol 159 1247 1253 1:CAS:528: DC%2BD3MXnvVCntLw%3D 11583952
12. W Dietmaier A Hartmann S Wallinger, et al. 1999 Multiple mutation analyses in single tumor cells with improved whole genome amplification Am J Pathol 154 83 95 1:CAS:528:DyaK1MXnsFCqug%3D%3D 9916922
13. NC Bae MH Chae MH Lee, et al. 2007 EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients Cancer Genet Cytogenet 173 107 113 10.1016/j.cancergencyto.2006.10.007 1:CAS:528:DC%2BD2sXitFOgsrg%3D 17321325 (Pubitemid 46281348)
14. AG Pallis A Voutsina A Kalikaki, et al. 2007 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer Br J Cancer 97 1560 1566 10.1038/sj.bjc.6604068 1:CAS:528:DC%2BD2sXhtlKmt7vN 18000506 (Pubitemid 350175853)
15. H Kimura Y Fujiwara T Sone, et al. 2006 High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non-small cell lung cancer patients Cancer Sci 97 642 648 10.1111/j.1349-7006.2006.00216.x 1:CAS:528:DC%2BD28XmsVOntLs%3D 16827805 (Pubitemid 44056613)
16. H Kimura M Suminoe K Kasahara, et al. 2007 Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA) Br J Cancer 97 778 784 10.1038/sj.bjc.6603949 1:CAS:528:DC%2BD2sXhtVWksLzP 17848912 (Pubitemid 47396294)
17. M Beau-Faller AM Ruppert AC Voegeli, et al. 2008 MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort J Thorac Oncol 3 331 339 10.1097/JTO. 0b013e318168d9d4 18379349
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (Pubitemid 30099779)
19. MN Balak Y Gong GJ Riely, et al. 2006 Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors Clin Cancer Res 12 6494 6501 10.1158/1078-0432.CCR-06-1570 1:CAS:528:DC%2BD28XhtFKitbrI 17085664 (Pubitemid 44799723)
20. T Kosaka Y Yatabe H Endoh, et al. 2006 Analysis of epidermal growth factor receptor gene mutation in patients with non small cell lung cancer and acquired resistance to gefitinib Clin Cancer Res 12 5764 5769 10.1158/1078-0432.CCR-06-0714 1:CAS:528:DC%2BD28XhtVartbvL 17020982 (Pubitemid 44629607)
21. CR Newton A Graham LE Heptinstall, et al. 1989 Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS) Nucleic Acids Res 17 2503 2516 10.1093/nar/17.7.2503 1:CAS:528:DyaL1MXktFyktbs%3D 2785681
22. D Whitcombe J Theaker SP Guy, et al. 1999 Detection of PCR products using self-probing amplicons and fluorescence Nat Biotechnol 17 804 807 10.1038/11751 1:CAS:528:DyaK1MXmtFahsr0%3D 10429248 (Pubitemid 29365111)
23. J Bean C Brennan JY Shih, et al. 2007 MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci USA 104 20932 20937 10.1073/pnas.0710370104 1:CAS:528:DC%2BD1cXktlyhsg%3D%3D 18093943
24. M Inukai S Toyooka S Ito, et al. 2006 Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer Cancer Res 66 7854 7858 10.1158/0008-5472.CAN-06-1951 1:CAS:528: DC%2BD28XotFWqsbo%3D 16912157 (Pubitemid 44299146)
25. JY Shih CH Gow PC Yang 2005 EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer N Engl J Med 353 2 207 208 10.1056/NEJM200507143530217 1:CAS:528:DC%2BD2MXmtFGnsrk%3D 16014893 (Pubitemid 41058355)
26. S Toyooka K Kiura T Mitsudomi 2005 EGFR mutation and response of lung cancer to gefitinib N Engl J Med 352 20 2136 10.1056/NEJM200505193522019 1:CAS:528:DC%2BD2MXkt1Kktbw%3D 15901872 author reply 2136 (Pubitemid 40664319)
27. DW Bell I Gore RA Okimoto, et al. 2005 Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR Nat Genet 37 12 1315 1316 10.1038/ng1671 1:CAS:528:DC%2BD2MXht1Ggsr7K 16258541 (Pubitemid 41722184)